cAMP Hunter™ Semaglutide Bioassay Kit
The cAMP Hunter™ Semaglutide Bioassay Kit provides an easy-to-use cell based assay to measure drug potency and detect neutralizing antibodies. This bioassay assesses ligand (e.g. Exendin-4) based on activation of GLP1R GPCR activity via detection of cAMP.
Catalog #: 95-0062Y2-00175
Size:
2-Plate
Unit Price: USD 1,989.00
Log in to see your actual price
Qty
Overview
Specifications
Documentation
Resources
Related Info
Biological Background
The Glucagon-Like Peptide-1 Receptor (GLP-1R) is a critical target for obesity research and drug discovery, with functional bioassays serving as essential tools for evaluating therapeutic potential. Semaglutide, a leading obesity research tool and breakthrough GLP-1 receptor agonist achieving 15-19% weight loss, represents the gold standard for metabolic therapeutics development.
This bioassay kit serves pharmaceutical companies developing GLP-1 receptor agonist therapies for diabetes, obesity, and cardiovascular disease. Applications include drug characterization, lot release testing, stability studies, and neutralizing antibody screening. The ready-to-use format accelerates results.
Eurofins DiscoverX's qualified kit has been optimized with Ozempic® to meet regulatory requirements, providing validated parameters including 97% accuracy, 8.7% repeatability, and 8.5% intermediate precision.
Product Highlights
- Qualified bioassay with comprehensive validation demonstrating 97% accuracy, 8.7% repeatability, and excellent linearity (R2 = 0.9990)
- Optimized and qualified with Ozempic® (semaglutide) ensuring reliable potency measurement and neutralizing antibody detection
- Ready-to-use cryopreserved CHO-K1 cells overexpressing human GLP-1R with EFC detection technology for sensitive results
- Complete kit includes cells, detection reagents, plating reagent, control agonist (exendin-4), and 96-well assay plates
- Proven inter-analyst reproducibility and day-to-day consistency with validated dilutional linearity across 50-150% range
cAMP Hunter Semaglutide Assay Principle
In the cAMP Hunter™ Semaglutide Bioassay Kit, CHO-K1 cells overexpressing human GLP-1R utilize the receptor's natural Gαs coupling to monitor activation. When stimulated by semaglutide, the receptor activates adenylyl cyclase, catalyzing ATP conversion to 3′-5′ cyclic adenosine monophosphate (cAMP). The resulting increase in intracellular cAMP is quantified using a homogeneous, gain-of-signal competitive immunoassay based on Enzyme Fragment Complementation (EFC) technology. Signal intensity correlates directly with cellular cAMP levels,greater GLP-1R activation produces higher cAMP concentrations and larger assay signals.
cAMP Hunter Semaglutide Qualification Data
The Semaglutide qualification data demonstrates comprehensive validation of the cAMP Hunter™ Semaglutide Bioassay Kit across critical performance parameters.
Validation studies include day-to-day repeatability assessment (8.3-8.4% RSD for signal-to-background and EC50), inter-analyst reproducibility testing, relative potency evaluation across 50-150% nominal concentrations, and dilutional linearity analysis (R2 = 0.9990). Performance metrics demonstrate 97% average recovery, 8.7% repeatability, and 8.5% intermediate precision.
All studies were conducted with Ozempic® and documented by qualified personnel, meeting regulatory specifications for accuracy, precision, and linearity requirements.
View qualification data
Neutralizing Antibody (NAb) Testing for Semaglutide
Performance metrics below highlight the cAMP Hunter™ Semaglutide Bioassay's neutralizing antibody screening functionality. The assay enables sensitive, quantitative detection of NAb responses, fundamental for evaluating continued therapeutic benefit and safety monitoring of semaglutide biosimilar therapies.
